Virginia Retirement Systems ET AL trimmed its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,300 shares of the specialty pharmaceutical company’s stock after selling 3,100 shares during the period. Virginia Retirement Systems ET AL owned about 0.07% of Jazz Pharmaceuticals worth $6,608,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its position in shares of Jazz Pharmaceuticals by 21.8% in the 3rd quarter. American Century Companies Inc. now owns 505,582 shares of the specialty pharmaceutical company’s stock worth $85,004,000 after purchasing an additional 90,521 shares during the period. Cadence Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $263,000. Advisory Services Network LLC raised its stake in shares of Jazz Pharmaceuticals by 10,200.0% during the 3rd quarter. Advisory Services Network LLC now owns 2,575 shares of the specialty pharmaceutical company’s stock worth $433,000 after acquiring an additional 2,550 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $494,000. Finally, Stratos Wealth Partners LTD. bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $106,000. 92.95% of the stock is owned by institutional investors.
Several research analysts recently commented on JAZZ shares. Evercore ISI reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Friday, July 13th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $203.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 7th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $191.94.
In other Jazz Pharmaceuticals news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $175.70, for a total transaction of $35,140.00. Following the transaction, the executive vice president now owns 25,572 shares in the company, valued at approximately $4,493,000.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,300 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $159.45, for a total transaction of $207,285.00. Following the transaction, the chief executive officer now owns 278,615 shares in the company, valued at approximately $44,425,161.75. The disclosure for this sale can be found here. Insiders have sold a total of 16,730 shares of company stock worth $2,796,532 in the last 90 days. 3.90% of the stock is currently owned by company insiders.
Shares of Jazz Pharmaceuticals stock opened at $145.57 on Friday. The company has a current ratio of 4.29, a quick ratio of 3.62 and a debt-to-equity ratio of 0.52. Jazz Pharmaceuticals PLC has a 12-month low of $130.15 and a 12-month high of $184.00. The company has a market cap of $8.47 billion, a price-to-earnings ratio of 12.16, a P/E/G ratio of 0.76 and a beta of 1.06.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business had revenue of $469.37 million for the quarter, compared to analyst estimates of $482.64 million. During the same quarter in the prior year, the business posted $3.22 EPS. Jazz Pharmaceuticals’s revenue for the quarter was up 14.0% compared to the same quarter last year. Research analysts forecast that Jazz Pharmaceuticals PLC will post 11.71 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Virginia Retirement Systems ET AL Lowers Holdings in Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/11/10/virginia-retirement-systems-et-al-lowers-holdings-in-jazz-pharmaceuticals-plc-jazz.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Story: How to calculate compound interest
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.